[Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference].
Molekularpathologie bei urologischen Tumoren : Empfehlungen der Konsenskonferenz der Internationalen Gesellschaft für Uropathologie (ISUP) 2019.
Bladder cancer
Kidney cancer
Molecular biomarker
Prostate cancer
Targeted therapy
Journal
Der Pathologe
ISSN: 1432-1963
Titre abrégé: Pathologe
Pays: Germany
ID NLM: 8006541
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
accepted:
07
12
2020
pubmed:
6
1
2021
medline:
4
5
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
Comprehensive understanding of molecular principles in cancer and the diversification of oncological therapy promise individual therapeutic concepts, which have not yet found their way into urogenital cancer therapy. In March 2019 the International Society of Urogenital Pathology (ISUP) therefore held a consensus conference on recommendations for molecular diagnostics of genitourinary tumors, which were published in five separate manuscripts and are summarized in this article.In preparation for the conference, a comprehensive survey of current practices for molecular testing of urogenital tumors was carried out by members of the ISUP. At the conference, the results and the corresponding background information were presented by five working groups and recommendations for action for diagnostics were developed. An agreement between 66% of the conference participants was defined as consensus. Das zunehmende Verständnis molekularer Grundlagen von Tumoren sowie der Fortschritt in der Diversifizierung der onkologischen Therapien versprechen individualisierte Therapieoptionen, welche bislang jedoch nur ansatzweise in die Therapieplanung von urologischen Tumoren eingegangen sind. Daher hat die Internationale Gesellschaft für Urologische Pathologie (ISUP) im März 2019 eine Konsenskonferenz zur Erarbeitung evidenzbasierter Handlungsempfehlungen zur molekularpathologischen Diagnostik beim Urothelkarzinom, Nierenzellkarzinom, Prostatakarzinom, Peniskarzinom und testikulären Keimzelltumoren durchgeführt. Die auf dieser Konsenskonferenz erarbeiteten Empfehlungen sind kürzlich in 5 separaten Manuskripten veröffentlich worden und werden in der vorliegenden Arbeit zusammengefasst.Im Rahmen der Konferenzvorbereitung wurde eine umfassende Umfrage zur derzeitigen Praxis molekularer Testungen bei urogenitalen Tumoren unter den Mitgliedern der ISUP durchgeführt. Auf der Konferenz wurden die Ergebnisse und die entsprechenden Hintergrundinformationen durch 5 Arbeitsgruppen präsentiert und Handlungsempfehlungen für die Diagnostik erarbeitet. Eine Übereinstimmung von 66 % der Konferenzteilnehmer wurde als Konsens definiert.
Autres résumés
Type: Publisher
(ger)
Das zunehmende Verständnis molekularer Grundlagen von Tumoren sowie der Fortschritt in der Diversifizierung der onkologischen Therapien versprechen individualisierte Therapieoptionen, welche bislang jedoch nur ansatzweise in die Therapieplanung von urologischen Tumoren eingegangen sind. Daher hat die Internationale Gesellschaft für Urologische Pathologie (ISUP) im März 2019 eine Konsenskonferenz zur Erarbeitung evidenzbasierter Handlungsempfehlungen zur molekularpathologischen Diagnostik beim Urothelkarzinom, Nierenzellkarzinom, Prostatakarzinom, Peniskarzinom und testikulären Keimzelltumoren durchgeführt. Die auf dieser Konsenskonferenz erarbeiteten Empfehlungen sind kürzlich in 5 separaten Manuskripten veröffentlich worden und werden in der vorliegenden Arbeit zusammengefasst.Im Rahmen der Konferenzvorbereitung wurde eine umfassende Umfrage zur derzeitigen Praxis molekularer Testungen bei urogenitalen Tumoren unter den Mitgliedern der ISUP durchgeführt. Auf der Konferenz wurden die Ergebnisse und die entsprechenden Hintergrundinformationen durch 5 Arbeitsgruppen präsentiert und Handlungsempfehlungen für die Diagnostik erarbeitet. Eine Übereinstimmung von 66 % der Konferenzteilnehmer wurde als Konsens definiert.
Identifiants
pubmed: 33398501
doi: 10.1007/s00292-020-00888-4
pii: 10.1007/s00292-020-00888-4
pmc: PMC8084837
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
310-318Références
Abida W, Cyrta J, Heller G et al (2019) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 116:11428–11436
pubmed: 31061129
Ahearn TU, Pettersson A, Ebot EM et al (2016) A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst 108(2):djv346
pubmed: 26615022
Al-Ahmadie HA, Iyer G, Lee BH et al (2016) Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet 48:356–358
pubmed: 26901067
pmcid: 4827439
Anderson CB, Lipsky M, Nandula SV et al (2019) Cytogenetic analysis of 130 renal oncocytomas identify three distinct and mutually exclusive diagnostic classes of chromosome aberrations. Genes Chromosomes Cancer. https://doi.org/10.1002/gcc.22766
doi: 10.1002/gcc.22766
pubmed: 31112346
pmcid: 6590296
Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038
pubmed: 25184630
pmcid: 4201502
Antonarakis ES, Shaukat F, Isaacsson Velho P et al (2019) Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol 75:378–382
pubmed: 30337059
Argani P (2015) MiT family translocation renal cell carcinoma. Semin Diagn Pathol 32:103–113
pubmed: 25758327
Azevedo R, Soares J, Peixoto A et al (2018) Circulating tumor cells in bladder cancer: emerging technologies and clinical implications foreseeing precision oncology. Urol Oncol 36:221–236
pubmed: 29530466
Balar AV, Castellano D, O’Donnell PH et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:1483–1492
pubmed: 28967485
pmcid: 28967485
Berlin A, Castro-Mesta JF, Rodriguez-Romo L et al (2017) Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis. Urol Oncol 35:499–506
pubmed: 28648414
Beukers W, Van Der Keur KA, Kandimalla R et al (2017) FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study. J Urol 197:1410–1418
pubmed: 28049011
Bonneville R, Krook MA, Kautto EA et al (2017) Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00073
doi: 10.1200/PO.17.00073
pubmed: 29850653
pmcid: 5972025
Brand TC, Zhang N, Crager MR et al (2016) Patient-specific meta-analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17-gene genomic prostate score. Urology 89:69–75
pubmed: 26723180
Brugarolas J (2014) Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol 32:1968–1976
pubmed: 24821879
pmcid: 4050206
Bubendorf L, Grilli B, Sauter G et al (2001) Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 116:79–86
pubmed: 11447756
Camparo P, Vasiliu V, Molinie V et al (2008) Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 32:656–670
pubmed: 18344867
Cancer Genome Atlas Research Network (2015) The molecular taxonomy of primary prostate cancer. Cell 163:1011–1025
Canete-Portillo S, Velazquez EF, Kristiansen G et al (2020) Report from the international Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers V: recommendations on the use of immunohistochemical and molecular biomarkers in penile cancer. Am J Surg Pathol 44(7):e80–e86
pubmed: 32235153
Cheng HH, Pritchard CC, Boyd T et al (2016) Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer. Eur Urol 69:992–995
pubmed: 26724258
Christensen E, Birkenkamp-Demtröder K, Sethi H et al (2019) Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 37:1547–1557
pubmed: 31059311
Conteduca V, Wetterskog D, Sharabiani MTA et al (2017) Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol 28:1508–1516
pubmed: 28472366
pmcid: 5834043
Cubilla AL, Lloveras B, Alejo M et al (2011) Value of p16(INK)4(a) in the pathology of invasive penile squamous cell carcinomas: a report of 202 cases. Am J Surg Pathol 35:253–261
pubmed: 21263246
Cuzick J, Berney DM, Fisher G et al (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106:1095–1099
pubmed: 22361632
pmcid: 3304411
Dunant N (2020) Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints. https://www.roche.com/media/releases/med-cor-2020-06-19.htm . Zugegriffen: 25. Okt. 2020
FDA (2020) FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer . Zugegriffen: 1. Juni 2020
Fernández-Nestosa MJ, Guimerà N, Sanchez DF et al (2020) Comparison of human papillomavirus genotypes in penile Intraepithelial neoplasia and associated lesions: LCM-PCR study of 87 lesions in 8 patients. Int J Surg Pathol 28:265–272
pubmed: 31735112
Gill AJ (2018) Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology 72:106–116
pubmed: 29239034
Gobbo S, Eble JN, Delahunt B et al (2010) Renal cell neoplasms of oncocytosis have distinct morphologic, immunohistochemical, and cytogenetic profiles. Am J Surg Pathol 34:620–626
pubmed: 20305535
Grasso CS, Wu YM, Robinson DR et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239–243
pubmed: 22722839
pmcid: 3396711
Guedes LB, Antonarakis ES, Schweizer MT et al (2017) MSH2 loss in primary prostate cancer. Clin Cancer Res 23:6863–6874
pubmed: 28790115
pmcid: 5690834
Hajdinjak T (2008) UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 26:646–651
pubmed: 18367109
Isharwal S, Hu W, Sarungbam J et al (2019) Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. J Pathol 248:260–265
pubmed: 30838648
pmcid: 6579631
Isharwal S, Huang H, Nanjangud G et al (2018) Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol 77:63–69
pubmed: 29601842
pmcid: 6019182
Jamaspishvili T, Berman DM, Ross AE et al (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15:222–234
pubmed: 29460925
pmcid: 7472658
Jia L, Carlo MI, Khan H et al (2019) Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases. Mod Pathol 32:1329–1343
pubmed: 30980040
pmcid: 6731129
Kammerer-Jacquet SF, Ahmad A, Møller H et al (2019) Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Mod Pathol 32:1303–1309
pubmed: 30976102
Kamoun A, De Reynies A, Allory Y et al (2020) A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77:420–433
pubmed: 31563503
Kinde I, Munari E, Faraj SF et al (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73:7162–7167
pubmed: 24121487
pmcid: 3966102
Krentz AD, Murphy MW, Kim S et al (2009) The DM domain protein DMRT1 is a dose-sensitive regulator of fetal germ cell proliferation and pluripotency. Proc Natl Acad Sci U S A 106:22323–22328
pubmed: 20007774
pmcid: 2799724
Lau HD, Chan E, Fan AC et al (2020) A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol 44:98–110
pubmed: 31524643
Leapman MS, Nguyen HG, Cowan JE et al (2018) Comparing prognostic utility of a single-marker immunohistochemistry approach with commercial gene expression profiling following radical prostatectomy. Eur Urol 74:668–675
pubmed: 30181067
Lokman U, Erickson AM, Vasarainen H et al (2018) PTEN loss but not ERG expression in diagnostic biopsies is associated with increased risk of progression and adverse surgical findings in men with prostate cancer on active surveillance. Eur Urol Focus 4:867–873
pubmed: 28753869
Looijenga LHJ, Van Der Kwast TH, Grignon D et al (2020) Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. IV. Current and future utilization of molecular-genetic tests for testicular germ cell tumors. Am J Surg Pathol 44(7):e66–e79
doi: 10.1097/PAS.0000000000001465
pubmed: 32205480
pmcid: 7289140
Lotan TL, Carvalho FL, Peskoe SB et al (2015) PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol 28:128–137
pubmed: 24993522
Lotan TL, Tomlins SA, Bismar TA et al (2020) Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. I. Molecular biomarkers in prostate cancer. Am J Surg Pathol 44(7):e15–e29
doi: 10.1097/PAS.0000000000001450
pubmed: 32044806
Marcus L, Lemery SJ, Keegan P et al (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25:3753–3758
pubmed: 30787022
Martignoni G, Gobbo S, Camparo P et al (2011) Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol 24:1313–1319
pubmed: 21602817
Mithal P, Allott E, Gerber L et al (2014) PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Urol 21:1209–1214
pubmed: 25099119
Mostert M, Rosenberg C, Stoop H et al (2000) Comparative genomic and in situ hybridization of germ cell tumors of the infantile testis. Lab Invest 80:1055–1064
pubmed: 10908150
Murray MJ, Coleman N (2012) Testicular cancer: a new generation of biomarkers for malignant germ cell tumours. Nat Rev Urol 9:298–300
pubmed: 22549310
Pal SK, Bergerot P, Dizman N et al (2018) Responses to alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol 74:124–128
pubmed: 29685646
Perlman EJ, Hu J, Ho D et al (2000) Genetic analysis of childhood endodermal sinus tumors by comparative genomic hybridization. J Pediatr Hematol Oncol 22:100–105
pubmed: 10779021
Piva F, Santoni M, Matrana MR et al (2015) BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Rev Mol Diagn 15:1201–1210
pubmed: 26166446
Pomerantz MM, Spisak S, Jia L et al (2017) The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer 123:3532–3539
pubmed: 28608931
pmcid: 5802871
Reis H, Szarvas T (2019) Therapieprädiktive Biomarker des Harnblasenkarzinoms. Pathologe 40:331–338
pubmed: 31705236
Risbridger GP, Taylor RA, Clouston D et al (2015) Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol 67:496–503
pubmed: 25154392
Robertson AG, Kim J, Al-Ahmadie H et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540–556.e525
pubmed: 28988769
pmcid: 5687509
Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215–1228
pubmed: 26000489
pmcid: 4484602
Rohan SM, Xiao Y, Liang Y et al (2011) Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol 24:1207–1220
pubmed: 21602815
Ross AE, Johnson MH, Yousefi K et al (2016) Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol 69:157–165
pubmed: 26058959
Rouprêt M, Fromont G, Azzouzi AR et al (2005) Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 65:1233–1237
pubmed: 15922421
Schmidt L, Duh FM, Chen F et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68–73
pubmed: 9140397
Schweizer MT, Antonarakis ES, Bismar TA et al (2019) Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations. JCO Precis Oncol. https://doi.org/10.1200/PO.18.00327
doi: 10.1200/PO.18.00327
pubmed: 31123724
pmcid: 6528668
Seiler R, Al Deen Ashab H, Erho N et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72:544–554
pubmed: 28390739
Shuch B, Vourganti S, Ricketts CJ et al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32:431–437
pubmed: 24378414
Sjodahl G, Abrahamsson J, Holmsten K et al (2019) Pathologic downstaging after neoadjuvant cisplatin-based combination chemotherapy in immunohistochemistry-defined molecular subtypes of bladder cancer. Eur Urol Suppl 18:e2106–e2107
Sperga M, Martinek P, Vanecek T et al (2013) Chromophobe renal cell carcinoma—chromosomal aberration variability and its relation to Paner grading system: an array CGH and FISH analysis of 37 cases. Virchows Arch 463:563–573
pubmed: 23913167
Sukov WR, Hodge JC, Lohse CM et al (2012) ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol 25:1516–1525
pubmed: 22743654
Suzman DL, Agrawal S, Ning YM et al (2019) FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist 24:563–569
pubmed: 30541754
Thompson S, Cioffi-Lavina M, Chapman-Fredricks J et al (2011) Distinction of high-grade neuroendocrine carcinoma/small cell carcinoma from conventional urothelial carcinoma of urinary bladder: an immunohistochemical approach. Appl Immunohistochem Mol Morphol 19:395–399
pubmed: 21617524
Turney A (2019) FDA approves first targeted therapy for metastatic bladder cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer . Zugegriffen: 1. Juni 2020
Ulbright TM, Tickoo SK, Berney DM et al (2014) Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the International Society of Urological Pathology consensus conference. Am J Surg Pathol 38:e50–e59
pubmed: 24832161
Van Echten J, Oosterhuis JW, Looijenga LH et al (1995) No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. Genes Chromosomes Cancer 14:133–144
pubmed: 8527395
Van Kessel KEM, Van Der Keur KA, Dyrskjot L et al (2018) Molecular markers increase precision of the European association of urology non-muscle-invasive bladder cancer progression risk groups. Clin Cancer Res 24:1586–1593
pubmed: 29367430
Velho PI, Lim D, Wang H et al (2019) Molecular characterization and clinical outcomes of primary Gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis Oncol. https://doi.org/10.1200/PO.19.00081
doi: 10.1200/PO.19.00081
pubmed: 31650100
Warrick JI, Knowles MA, Yves A et al (2020) Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. II. Molecular pathology of bladder cancer: progress and challenges. Am J Surg Pathol 44(7):e30–e46
doi: 10.1097/PAS.0000000000001453
pubmed: 32091435
Williamson SR, Gill AJ, Argani P et al (2020) Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. III. Molecular pathology of kidney cancer. Am J Surg Pathol 44(7):e47–e65
doi: 10.1097/PAS.0000000000001476
pubmed: 32251007
Xu J, Reznik E, Lee HJ et al (2019) Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. Elife 8:e38986
pubmed: 30924768
pmcid: 6459676
Zhong M, Tian W, Zhuge J et al (2015) Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol 39:127–131
pubmed: 25118812